ProCE Banner Activity

IDEA: Pooled Analysis of Adjuvant Oxaliplatin for 3 vs 6 Mos in Stage III Colon Cancer

Slideset Download
Conference Coverage
In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.

Released: June 05, 2017

Expiration: June 04, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology